Advantage Alpha Capital Partners LP Sells 14,350 Shares of Encompass Health Co. (NYSE:EHC)

Advantage Alpha Capital Partners LP cut its holdings in Encompass Health Co. (NYSE:EHC - Free Report) by 16.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 75,435 shares of the company's stock after selling 14,350 shares during the quarter. Encompass Health makes up 1.7% of Advantage Alpha Capital Partners LP's portfolio, making the stock its 8th largest position. Advantage Alpha Capital Partners LP owned 0.07% of Encompass Health worth $7,290,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in EHC. UMB Bank n.a. raised its stake in shares of Encompass Health by 387.7% during the third quarter. UMB Bank n.a. now owns 317 shares of the company's stock worth $31,000 after buying an additional 252 shares during the last quarter. V Square Quantitative Management LLC boosted its position in shares of Encompass Health by 53.0% in the 3rd quarter. V Square Quantitative Management LLC now owns 404 shares of the company's stock worth $39,000 after purchasing an additional 140 shares during the last quarter. Oakworth Capital Inc. bought a new stake in Encompass Health in the second quarter valued at about $40,000. Avior Wealth Management LLC acquired a new position in Encompass Health in the third quarter valued at about $40,000. Finally, Benjamin F. Edwards & Company Inc. grew its position in shares of Encompass Health by 58.9% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 534 shares of the company's stock worth $46,000 after buying an additional 198 shares during the period. 97.25% of the stock is owned by institutional investors.

Encompass Health Stock Up 1.7 %

NYSE EHC traded up $1.77 during trading on Tuesday, hitting $103.77. The stock had a trading volume of 546,807 shares, compared to its average volume of 642,340. Encompass Health Co. has a 12 month low of $63.78 and a 12 month high of $104.55. The company has a debt-to-equity ratio of 0.88, a quick ratio of 1.04 and a current ratio of 1.04. The company's 50-day moving average price is $97.28 and its two-hundred day moving average price is $90.99. The company has a market capitalization of $10.45 billion, a PE ratio of 25.07, a P/E/G ratio of 1.34 and a beta of 0.88.

Encompass Health (NYSE:EHC - Get Free Report) last announced its quarterly earnings data on Monday, October 28th. The company reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $0.94 by $0.09. Encompass Health had a net margin of 8.10% and a return on equity of 17.60%. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.33 billion. During the same quarter in the previous year, the firm posted $0.86 earnings per share. The firm's revenue for the quarter was up 11.9% on a year-over-year basis. As a group, sell-side analysts forecast that Encompass Health Co. will post 4.29 EPS for the current year.

Encompass Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Thursday, January 2nd will be issued a dividend of $0.17 per share. The ex-dividend date is Thursday, January 2nd. This represents a $0.68 annualized dividend and a yield of 0.66%. Encompass Health's payout ratio is presently 16.43%.

Wall Street Analysts Forecast Growth

Several brokerages have commented on EHC. Stephens reaffirmed an "overweight" rating and issued a $105.00 target price on shares of Encompass Health in a research note on Tuesday, August 6th. KeyCorp raised their price objective on Encompass Health from $115.00 to $117.00 and gave the stock an "overweight" rating in a research note on Tuesday, October 29th. Truist Financial reissued a "buy" rating and issued a $116.00 target price (up from $108.00) on shares of Encompass Health in a research note on Wednesday, October 30th. Royal Bank of Canada raised their price target on Encompass Health from $105.00 to $110.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 30th. Finally, UBS Group lifted their price objective on Encompass Health from $100.00 to $110.00 and gave the company a "buy" rating in a report on Wednesday, September 25th. Nine investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $107.11.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.